NCT02306161 2026-04-13
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT02567435 2026-04-13
Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04994132 2026-02-17
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT06820957 2026-02-17
Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body
Children's Oncology Group
Phase 2/3 Active not recruiting
NCT01871766 2025-12-17
Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
St. Jude Children's Research Hospital
Phase 2 Active not recruiting
NCT04388839 2025-11-26
Evolutionary Therapy for Rhabdomyosarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT00077285 2025-11-04
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting